Nintedanib
- Generic Name
- Nintedanib
- Brand Names
- Ofev, Vargatef, Nintedanib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C31H33N5O4
- CAS Number
- 656247-17-5
- Unique Ingredient Identifier
- G6HRD2P839
- Background
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only tw...
- Indication
Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) and to slow declining pulmonary function in patients with systemic sclerosis-associated interstitial lung disease. It is also indicated for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype.
...
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Respiratory Function Impaired, Chronic Progressive Fibrosing Interstitial Lung Disease, Locally advanced Non-Small Cell Lung Carcinoma (NSCLC), Locally recurrent Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Non-Small Cell Lung Carcinoma (NSCLC)
- Associated Therapies
- -
Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2014-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 34
- Registration Number
- NCT01679613
- Locations
- 🇩🇪
1199.161.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 51
- Registration Number
- NCT01658462
- Locations
- 🇫🇷
Centre Alexis Vautrin, Vandoeuvre Les Nancy, France
🇫🇷Centre Léonard de Vinci, Dechy, France
🇫🇷Institut Jean Godinot, Reims, France
Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 752
- Registration Number
- NCT01619085
- Locations
- 🇧🇪
Yvoir - UNIV UCL de Mont-Godinne, Yvoir, Belgium
🇨🇱Instituto Nacional del Tórax, Santiago de Chile, Chile
🇨🇳Peking University People's Hospital, Beijing, China
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT01417156
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
- Conditions
- Endometrial Undifferentiated CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Transitional Cell CarcinomaEndometrial Squamous Cell CarcinomaMalignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmEndometrial Mucinous AdenocarcinomaRecurrent Uterine Corpus Carcinoma
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 37
- Registration Number
- NCT01225887
- Locations
- 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Bay Area Medical Center, Marinette, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.